(S)-2-hydroxy-6<<(phenylmethoxy)carbonyl>amino>hexanoic acid methyl ester | 107492-32-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-2-hydroxy-6<<(phenylmethoxy)carbonyl>amino>hexanoic acid methyl ester
• 英文别名: (S)-6-[[(phenylmethoxy)carbonyl]anzino]-2-hydroxyhexanoic acid methyl ester；(S)-6-[[(phenylmethoxy)carbonyl]amino]-2-hydroxyhexanoic acid, methyl ester；methyl (2S)-2-hydroxy-6-(phenylmethoxycarbonylamino)hexanoate
• CAS: 107492-32-0
• 化学式: C₁₅H₂₁NO₅
• 分子量: 295.335
• InChiKey: UCHSSYIJWXAHCI-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.62
• 重原子数：
  21.0
• 可旋转键数：
  8.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  84.86
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  (S)-2-hydroxy-6<<(phenylmethoxy)carbonyl>amino>hexanoic acid methyl ester 在 palladium on activated charcoal 4-二甲氨基吡啶 、 sodium hydroxide 、 sodium periodate 、 氢气 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 为溶剂， 反应 27.67h， 生成 2-[[(2S)-6-amino-2-[hydroxy(4-phenylbutyl)phosphoryl]oxyhexanoyl]-(2,3-dihydro-1H-inden-2-yl)amino]acetic acid
  参考文献：
  名称：

  (Phosphinyloxy)acyl amino acid inhibitors of angiotensin converting enzyme. 2. Terminal amino acid analogs of (S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]oxy]-1-oxohexyl]-L-proline

  摘要：

  Analogues of (S)-1-[6-amino-2[[hydroxy(4-phenylbutyl)phosphinyl] oxy]-1-oxohexyl]-L-proline (1, SQ 29,852) in which the terminal proline residue has been replaced by a variety of substituted and heteroatom-substituted prolines, N-arylglycines, N-cycloalkylglycines, and bicyclic amino acids have been synthesized and evaluated as inhibitors of angiotensin converting enzyme in vitro and in vivo. In general, the addition of lipophilic substituents to the 4-position of proline of the parent phosphonate 1 resulted in substantial increases in in vitro activity. The largest improvements were observed in the case of cis-benzyl (36-fold) and dithioketal (24-fold) analogues 2r and 2x, respectively. These enhancements of in vitro activity were accompanied by modest increases (2-3.5-fold) in in vivo (iv) activity. Among the various terminal amino acid replacements examined in this study, the indoline-based analogue 2i was by far the most potent compound on iv administration in the normotensive rat.

  DOI：

  10.1021/jm00167a028
• 作为产物：
  描述：

  重氮甲烷 、 N(epsilon)-苄氧羰基-L-氧基赖氨酸 在 溶剂黄146 作用下， 以 乙酸乙酯 为溶剂， 生成 (S)-2-hydroxy-6<<(phenylmethoxy)carbonyl>amino>hexanoic acid methyl ester
  参考文献：
  名称：

  Substituted aminoalkanoylaminoalkyl phosphonate angiotensin converting

  摘要：

  公式为##STR1##的化合物中，X是各种氨基或亚氨基酸和酯。这些化合物由于其抑制血管紧张素转化酶的活性而可用作降压药物，根据X的定义，它们也可能由于其脑啡肽酶抑制活性而用作镇痛药。

  公开号：

  US04849414A1

文献信息

• [EN] POLYBIOTIN COMPOUNDS FOR MAGNETIC RESONANCE IMAGINING AND DRUG DELIVERY<br/>[FR] COMPOSES DE POLYBIOTINE POUR IRM ET ADMINISTRATION DE MEDICAMENTS
  申请人：GEN HOSPITAL CORP

  公开号：WO2005032598A1

  公开（公告）日：2005-04-14

  The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention.

  该发明涉及一般用作成像剂和药物传递剂的含生物素化合物。该发明的另一个方面涉及上述化合物螯合到金属原子上。在一个优选实施例中，金属原子是钆。该发明的另一个方面涉及一种包含三个生物素基团和一个与杂环核共价结合的药物剂的化合物。在某些实施例中，药物剂是抗生素、抗病毒药物或放射性核素。本发明的另一个方面涉及一种涉及向哺乳动物施用该发明化合物以治疗疾病的方法。本发明的另一个方面涉及使用该发明化合物获得磁共振图像的方法。
• KARANEWSKY, DONALD S.;BADIA, MICHAEL C.;CUSHMAN, DAVID W.;DEFORREST, JACK+, J. MED. CHEM., 33,(1990) N, C. 1459-1469
  作者：KARANEWSKY, DONALD S.、BADIA, MICHAEL C.、CUSHMAN, DAVID W.、DEFORREST, JACK+

  DOI：——

  日期：——